GO
Loading...

Biogen Idec Inc

More

  • Biogen shares fall after Tecfidera patient dies Wednesday, 22 Oct 2014 | 11:48 AM ET

    The patient, who was taking Tecfidera, died earlier this month.

  • Oct 22- Biogen Idec Inc on Wednesday reported sales of its big-selling new multiple sclerosis drug, Tecfidera, that fell short of Wall Street's lofty expectations, and the company confirmed a serious brain infection in a patient who took the oral medication, sending its shares about 8 percent lower. Shares of the U.S. biotechnology firm fell $24.29 to $302.48 on...

  • Late Tuesday, both Yahoo Inc and Broadcom beat on revenue. Dow component Boeing edged 0.3 percent higher to $127.50 after its results, while Dow advanced 4 percent to $50.13. Yahoo climbed 5.4 percent to $42.34 while Broadcom added 6.3 percent to $39.70.

  • Oct 22- Sales of Biogen Idec Inc's big-selling new oral multiple sclerosis drug Tecfidera fell short of lofty Wall Street estimates for the first time and its shares fell nearly 3 percent, even as the company reported higher-than-expected third-quarter profit and raised its full-year earnings forecast. Biogen raised its full-year adjusted earnings...

  • Early movers: BA, DOW, SWK, TSLA, YHOO Wednesday, 22 Oct 2014 | 8:41 AM ET
    A trader works on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • NEW YORK, Oct 22- Boeing Co and Dow Chemical were among the biggest movers of Wednesday's premarket session, with both stocks higher in the wake of strong results. Dow Chemical rose 2.7 percent to $49.50 before the bell after the company also reported better-than-expected earnings, helped by higher sales in its plastics and performance materials business...

  • Oct 22- Biogen Idec Inc on Wednesday reported much higher-than-expected third-quarter profit and the company raised its full-year earnings forecast, even as its big-selling new oral multiple sclerosis drug Tecfidera fell short of lofty Wall Street estimates for the first time. Citing updated business development expectations, Biogen raised its...

  • Oct 22- Biogen Idec Inc on Wednesday reported much higher third-quarter profit and revenue, even as its big-selling new oral multiple sclerosis drug Tecfidera fell short of lofty Wall Street estimates for the first time. The U.S. biotechnology company's net profit jumped to $856.1 million, or $3.62 per share, from $487.6 million, or $2.05 per share, a year ago.

  • Earnings set to drive markets again Wednesday, 22 Oct 2014 | 5:55 AM ET
    Traders on the floor of the New York Stock Exchange.

    Earnings news will take center stage Wednesday after another day of strong stock market gains cemented the view that the worst is over.

  • Earnings set to take markets' center stage Tuesday, 21 Oct 2014 | 7:29 PM ET
    Traders on the floor of the New York Stock Exchange.

    Earnings news will take center stage Wednesday after another day of strong stock market gains cemented the view that the worst is over.

  • Oct 16- Medical device and drug maker Baxter International Inc reported a higher-than-expected quarterly profit, as sales in its medical products business continued to grow. The company, whose profit topped expectations for the fourth straight quarter, cut its 2014 earnings forecast to $4.86- $4.89 per share to exclude gains from its vaccine business that it...

  • The first, Esbriet, was developed by InterMune Inc, which Switzerland- based Roche Holding AG agreed to buy for $8.3 billion in August, banking largely on the treatment's potential. The agency's decision marks a crucial milestone in the management of the disease, which affects about 100,000 people in the United States. Roche's drug, known generically as...

  • *Shire shares tumble as AbbVie reconsiders bid. NEW YORK, Oct 15- U.S. stocks dropped on Wednesday as economic data buttressed worries over the health of the world economy and signs emerged of slowing merger activity. Worries about a lethargic global economy weren't helped by data that showed U.S. retail sales and producer prices fell in September, while...

  • LONDON, Oct 8- A pioneering cannabis drug developed by British firm GW Pharmaceuticals for treating spasticity in multiple sclerosis has been rejected as not cost-effective in the company's home market. The National Institute for Health and Care Excellence, which determines if medicines are worth using on England's state health service, said on Wednesday...

  • Cramer: Stocks reflect America’s innovative spirit Wednesday, 24 Sep 2014 | 6:21 PM ET

    If you’re looking for stock ideas, Cramer says thanks to good ol’ American ingenuity, this sector is bursting with them.

  • US STOCKS-Biotechs climb after two-day drop Wednesday, 24 Sep 2014 | 1:48 PM ET

    NEW YORK, Sept 24- Biotech stocks are moving higher on Wednesday, bouncing back from a two-day drop, helped by gains in Gilead Sciences after trial results for the company's HIV treatment.

  • 3 top biotech stocks with big upside: Pro Friday, 5 Sep 2014 | 2:10 PM ET
    A multiple sclerosis drug is manufactured at the Biogen Idec plant in Cambridge, Mass.

    Three biotech stocks have plenty of potential, John Schroer of Allianz Global Investors says.

  • Aug 27- Roche Holding AG's planned $8 billion purchase of InterMune Inc is centered around hopes for blockbuster sales of its lung drug, but the smaller company's development pipeline may end up giving the Swiss drugmaker a far bigger bang for its buck.

  • Bankers and lawyers providing takeover advice said on Monday that Burger King Worldwide Inc's intention to move its tax domicile overseas through a so-called inversion deal- in this case the purchase of Canada's Tim Hortons- shouldn't be seen as a sign of a lot more deals to come.

  • Aug 21- Baxter International Inc said a more potent version of its flagship blood disorder drug Advate met the main goal in a late-stage study.